Innovation in digital health tools, including mobile health apps and wearable sensors, bring new approaches to the management of health conditions. Digital therapeutics to treat human disease are being approved by regulatory agencies around the world and routes to reimbursement are being established […]
How Health-Related Social Media Can Complement Traditional Real-World Evidence Approaches to Offer Unique Patient Insights
Traditional real-world evidence (RWE) is based on data collected in normal clinical practice outside of randomized controlled trials. It is used to complement clinical data in regulatory and health technology assessment submissions. This data is most often generated through retrospective or […]
What You Need to Know About Real-World Databases in Japan
Valuable information for real-world evidence generation can be gleaned from healthcare databases, and the number of databases available continues to expand. Knowing the right data to answer the right question is critical in effective study design. While much is known about use and access of data […]
Managing Diabetic Health Outcomes Remotely
Changing healthcare landscapes allow healthcare providers and their patients more options for care than ever before. Integrating virtual care options into the long-term care of diabetic patients can have a significant and measurable impact on both clinical and financial outcomes within this […]
Artificial Intelligence (AI) in Medical Diagnostics Market by Component (Software, Service), Application (In Vivo, Radiology, OBGY,MRI, CT, Ultrasound, IVD), End User (Hospital, Diagnostic Laboratory, Diagnostic Imaging Center)- Global Forecast to 2025
Report Highlights: The global AI in medical diagnostics market is projected to reach USD 3,868 million by 2025 from USD 505 million in 2020, at a CAGR of 50.2% during the forecast period. Growth in this market is primarily driven by government initiatives to increase the adoption of AI-based […]
Learn the fundamentals of Real World Evidence in Oncology Drug Development
Uses of real world data have played a role in every stage of clinical development from pre-clinical assessment of unmet need, to comparative effectiveness analysis for market access. Challenges commonly faced by clinical development in oncology make methods involving real world evidence prized […]
The Use of Medicines in the U.S.
Spending and Usage Trends and Outlook to 2025 According to a new report from the IQVIA Institute for Human Data Science – The Use of Medicines in the U.S. – the U.S. health system demonstrated resilience and flexibility during 2020, recovering toward its pre-pandemic levels of activity and […]
Advanced HCP Targeting
Precise HCP targeting is critical to maximizing your sales force and marketing activity investment. Explore IQVIA’s holistic HCP targeting solution, purpose-built to address today’s evolving market. Download the Insight Brief and learn how to: Create a true market opportunity assessment […]
10 Critical Questions to Ask When Evaluating a PE Analysis
In this free White Paper, we are going to walk step-by-step through: The ONE type of pharmacoeconomic analysis you cannot do without when evaluating new drugs This type of analysis lets you directly compare all of the costs and health benefits of drugs used to treat different disease states, […]
Market access for regenerative medicines and rare disease therapies
Market access strategies for regenerative medicines, and rare and orphan disease treatments are particularly complex. This collection of case studies illustrates some of the challenges and opportunities for manufacturers, including: mapping the policy landscape and understand evolving payer […]
What is Data Fabric Design?
Explore Data Fabric Design “Every data and analytics leader’s goal is to reach decisions, actions, and output faster. Automation is inevitable to achieve this. In a recent Gartner survey, 50% of data and analytics leaders want to entirely automate data integration, a third want to automate data […]
International Profiles of Health Care Systems
How are healthcare systems around the world organised? This very useful resource provides concise profiles of healthcare systems in 20 countries. Key topics covered include: How universal health coverage works How the delivery system is organised and providers are paid Strategies to […]
Guidebook: How to Use Real World Evidence to Enrich Registries
How do you successfully use existing registries to generate impactful evidence? This article breaks down the three key ingredients to the successful creation of evidence generation strategies. Regulatory agencies, payers, and the scientific community are all encouraging: pharma sponsors to […]
Strengthening the Accelerated Approval Pathway: An Analysis of Potential Policy Reforms and Their Impact on Uncertainty, Access, Innovation, and Costs.
The Institute for Clinical and Economic Review (ICER), in collaboration with researchers from the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center, has published a new white paper: “Strengthening the Accelerated Approval Pathway: An Analysis of Potential Policy Reforms and Their Impact on […]
How Life Science Companies can Engage Stakeholders with a Hybrid Virtual Approach
In this white paper you will learn how adopting a hybrid approach to engagement can create efficiency gains and enhance communications across a range of functions in life sciences. Download the white paper to learn more about: The trend towards asynchronous (over-time) virtual engagement […]
Explore Transformative Real World Data Sources
Leverage RWE to cut research costs, improve insights, and more When you combine the growing acceptance of real world data (RWD) with challenges in the pharma industry – such as the need to accelerate speed to market, conduct studies efficiently, and secure payer approvals – the value of […]
Using Real-world Data to Better Understand the Patient Journey
Understanding how patients navigate and experience the health care system is essential to maximizing the potential of novel treatments and services. But even with real-world data, it is hard to identify the key moments in care that have the greatest impact on treatment decision-making. This is where […]
What to Look for in an Informatics Platform for Life Sciences R&D
As modern life science R&D becomes more complex, variable, and fluid, organizations need informatics platforms that can keep up. Learn about the five essential capabilities of a life science R&D informatics platform in this whitepaper from Benchling. Get the whitepaper to learn about: […]
Beyond The Field: Evolving Field Medical Engagement And Talent For The Future
At the MAPS EMEA 2020 Annual Meeting, 150+ delegates attended a special session that discussed how Field Medical engagement has evolved as a result of COVID-19. The group from a number of different Medical Affairs organizations also analyzed what the future of talent acquisition and retention is […]
Innovating the Delivery of Patient Support: Branded Patient Support programs for Today’s Health Consumer
There is no question that COVID-19 transformed how we collectively delivered care in 2020. Global venture capital funding for digital health companies in the first nine months of 2020, alone, was a record-breaking $10.3 billion with top-funded categories of telemedicine, data analytics and mHealth […]
Healthcare Cost Containment: Best Practices & Recommendations
While the full impact of the novel coronavirus (COVID-19) is not yet known, certain things are clear. Healthcare is forever changed. As states contain the spread of COVID-19, re-open economies, and grapple with how to move forward, it is paramount to ensure the sustainability and fiscal integrity of […]
How Payers Can Outpace Market Competition
Discover how other payers are using competitive insights to fuel better business decisions. Some payers are using competitive intelligence and are making better business decisions, leaving payers who don't have these insights at a disadvantage. Deeper insights elevate decision-making power in […]
2021 State of Health: Bracing for Impact
COVID-19 care deferrals lead to three major boomerang conditions that payers and providers must proactively address COVID-19’s hidden victims—those who avoided or deferred care during the pandemic—will increasingly return to the healthcare system, and many will be diagnosed with new conditions at […]
Need more pipeline productivity?
For the past decade, the success of Phase 3 trials has hovered around 30-35%. Innovative trial designs have the potential to improve probability of success, shorten trial durations, and reduce trial costs. Yet, Cytel’s recent research uncovered that traditional development team approaches to the […]
EHR Data Enrichment: Enhancing the Value of RWD
Heart failure (HF) is a complex, debilitating syndrome affecting an estimated 63 million people worldwide (GBD 2016). Its impact on patients and health systems continues to increase in tandem with rising rates of obesity, hypertension, and diabetes in an aging population. Download the white paper […]
Social Determinants of Health in the Time of COVID-19: A 2021 Update
Socioeconomic and place-based factors – collectively known as the social determinants of health (SDoH) – continue to figure prominently in the ongoing COVID-19 pandemic. The impact of social determinant risk has only been amplified as the pandemic continues into 2021. Download the e-Book […]
Will US payers give more consideration to PRO data when making their coverage and formulary decisions?
With an increased focus on patient centricity and the 21st Century Cures Act, the US Food and Drug Administration (FDA) has been advocating for patient-focused drug development through a series of guidance documents to “ensure that patient’s experiences, perspectives, needs, and priorities are […]
Artificial Intelligence Can Boost Reliability and Speed of Medical Imaging Analysis in Clinical Trials
Pharmaceutical firms face many challenges in bringing their products through clinical trials — from enrollment delays to data quality issues — and every advantage can make a difference. In image analysis, sponsors can gain a critical advantage by leveraging artificial intelligence/machine […]
Health Technology Assessment in the U.S. – A Vision for the Future
The USC Schaeffer Center for Health Policy & Economics and the Aspen Institute have together established an advisory panel to consider how the U.S. can better link the price of health technologies to the benefits they provide to patients while ensuring a sustainable healthcare ecosystem that […]
Follow the Dollar Part II
Understanding the Cost of Brand Medicines Administered to Commercially Isured Patients in Hospital Outpatient Departments A new report uncovers the system of incentives that lead hospitals to drive up costs for patients and employers by marking up the price of medicines. While the supply chain for […]
